CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 64 enrolled
Drug / intervention
donepezil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00267163
NCT00267163Phase 4Completed
CompareCT.gov

Brain Imaging and Mental Disorders of Aging Intervention

National Institute on Aging (NIA)·interventional·Posted Dec 20, 2005·Updated Aug 29, 2008

In Brief

A Phase 4 clinical trial evaluating donepezil and Placebo for Cognition Disorders. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The goal of this project is to determine if a cholinesterase inhibitor is more effective than placebo in delaying cognitive and brain functional decline in people at risk for Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognition Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2005
Enrollment StartSep 1, 2000
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.5 years ago

Interventions

donepezildrug

Placebodrug